Q3 2024 · 13F-HR
Atlas Venture Life Science Advisors, LLCholdings as filed
Filed 2024-11-13 · accession 0001104659-24-116967
$1.08B
Reported value
14
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $288.1M | 26.7% | 8,020,136 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $231.7M | 21.5% | 4,896,462 | Common | SOLE |
| 88427A107 | — | Third Harmonic Bio, Inc. | $147.8M | 13.7% | 10,907,859 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $123.3M | 11.4% | 2,509,456 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio, Inc. | $93.3M | 8.65% | 2,092,106 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals, Inc. | $89.6M | 8.30% | 6,430,257 | Common | SOLE |
| 500946108 | KRRO | Korro Bio, Inc. | $38.0M | 3.52% | 1,137,149 | Common | SOLE |
| 37148K100 | GBIOGBX | Generation Bio, Co. | $20.5M | 1.90% | 8,279,484 | Common | SOLE |
| 92673K108 | VIGL | Vigil Neuroscience, Inc. | $19.8M | 1.84% | 5,836,874 | Common | SOLE |
| 878972108 | TECX | Tectonic Therapeutics, Inc. | $11.5M | 1.06% | 378,447 | Common | SOLE |
| 45175G108 | — | Ikena Oncology, Inc. | $8.7M | 0.80% | 5,018,178 | Common | SOLE |
| 008064107 | — | Aerovate Therapeutics, Inc. | $3.8M | 0.35% | 1,799,232 | Common | SOLE |
| 252828108 | DNTH | Dianthus Therapeutics, Inc. | $2.1M | 0.20% | 76,979 | Common | SOLE |
| 84833T103 | SPRO | Spero Therapeutics, Inc. | $539,866 | 0.05% | 402,885 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.